Revisiting retinoic acid in AML therapy: mechanisms of action and rational combination strategies

British Journal of Cancer · Published 2026-07-02 · DOI 10.1038/s41416-026-03512-z

Free full text

Authors (7)

Setenay Gupse Özcan, Clara Stanko, Lukasz Szymanski, Martin Fischer, Annamaria Brioli, Arthur Zelent, Tino Schenk

Abstract

PubPorta does not have an abstract for this article yet.

Read the article at the publisher →

Publication details

Year

2026

Citation

Özcan, S., Stanko, C., Szymanski, L., et al. (2026). Revisiting retinoic acid in AML therapy: mechanisms of action and rational combination strategies. British Journal of Cancer. https://doi.org/10.1038/s41416-026-03512-z

Related articles

• Circulating tumor-associated autoantibody signatures for diagnosis and prognosis in small-cell lung cancer and lung adenocarcinoma · British Journal of Cancer · 2026 · Same journal
• High KPNA2 expression predicts poor prognosis in pathological T4 colorectal cancer by importing c-Myc into the nucleus to suppress p53-dependent p21 expression · British Journal of Cancer · 2026 · Same journal
• Efficacy and safety of infigratinib in patients with refractory advanced gastric or gastroesophageal junction adenocarcinoma harboring FGFR2 gene amplification: a single-arm, multicenter phase 2 trial · British Journal of Cancer · 2026 · Same journal
• Reactivation of DRP1 plays a functional role in resistance to MEK inhibition in pancreatic cancer cells · British Journal of Cancer · 2026 · Same journal
• Interpreting the adverse esophageal and colorectal findings in the Cancer Risk in Vegetarians Consortium · British Journal of Cancer · 2026 · Same journal
• AKR1B10 as a serum marker for diagnosis and postoperative monitoring of hepatocellular carcinoma · British Journal of Cancer · 2026 · Same journal
• Targeting Siglec-engaging immunosuppressive sialoglycans to suppress prostate cancer bone metastasis · British Journal of Cancer · 2026 · Same journal
• Signatures of micropeptides encoded by lncRNAs in cancer progression and metastasis · British Journal of Cancer · 2026 · Same journal
• Can national lung cancer screening programs be implemented without exacerbating social disparities? · British Journal of Cancer · 2026 · Same journal
• Olaparib in HR-deficient, metastatic triple-negative breast and platinum-sensitive relapsed ovarian cancers without germline mutations in BRCA1/2: phase 2 EMBRACE trial · British Journal of Cancer · 2026 · Same journal